Scisparc Ltd Surges on Market Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Scisparc Ltd experienced a price increase of 11.94%, crossing above its 20-day SMA amid positive market conditions.
The Nasdaq-100 saw a slight gain of 0.13%, contributing to the overall market strength that supported Scisparc's upward movement.
This rise indicates a favorable sentiment towards the stock, suggesting potential investor confidence in the company's future performance.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
